or isomethadone or ketazocine or ketobemidone or ketogan or kyotorphin or lefetamine or levacetylmethadol or levomethadone or Levorphanol or Meperidine or Meptazinol or metazocine or Methadone or "Methadyl Acetate" or methylsamidorphan or Morphine or "morphinomimetic agent*" or "morphinomimetic drug*" or morphinone or Nalbuphine or narcotic* or nicocodine or nicomorphine or noracymethadol or norbuprenorphine
or Dihydromorphine or dimethylthiambutene or Diphenoxylate or dipipanone or enadoline or eptazocine or ethylketazocine or Ethylketocyclazocine or Ethylmorphine or etonitazene or Etorphine or etoxeridine or faxeladol or Fentanyl or furethidine or gelonida or Heroin or Hydrocodone or isalmadol or isomethadone or ketazocine or ketobemidone or ketogan or kyotorphin or lefetamine or levacetylmethadol or levomethadone
Pharmacological Investigations of the Dissociative ‘Legal Highs’ Diphenidine, Methoxphenidine and Analogues 1,2-Diarylethylamines including lanicemine, lefetamine, and remacemide have clinical relevance in a range of therapeutic areas including pain management, epilepsy, neurodegenerative disease and depression. More recently 1,2-diarylethylamines have been sold as 'legal highs' in a number
Lefetamine: new abuse of an old drug--clinical evaluation of opioid activity. Lefetamine (SPA) combining amphetamine with opioid-like effects, a drug of wide abuse in Japan in the fifties, has now been introduced as such in Italy. In this study the drug was tested to verify its resemblance to opiates. Ten lefetamine abusers were hospitalized and then subjected to naloxone- and pentazocine-tests and detoxified. Moreover, lefetamine was administered to ten opiate addicts with an acute withdrawal syndrome and to ten methadone-treated addicts. The naloxone-test was positive and pentazocine could be substituted for lefetamine. Lefetamine was able to relieve opiate withdrawal and did not precipitate withdrawal symptoms in stabilized opiate addicts. It is concluded that lefetamine may act as an opioid
Opiate detoxification of methadone maintenance patients using lefetamine, clonidine and buprenorphine. Thirty-nine methadone maintenance patients were included in a 9-day, double blind, randomized, inpatient detoxification trial. Methadone was tapered to 10 mg/day and then patients were assigned to one of these 3 protocols: clonidine (0.3-0.9 mg/day), lefetamine (60-240 mg/day), buprenorphine (0.15-0.9 mg/day). Buprenorphine treatment was significantly superior to clonidine and to lefetamine (F = 3.96 df = 2, 29 P < 0.05) in controlling objective, subjective and psychological withdrawal symptomatology. Clonidine was more effective than lefetamine in suppressing withdrawal in the first 3 days of treatment (day 3: F = 4.10 df = 2, 30 P < 0.05), and this trend was apparent on the objective